Success Stories: A Scientist Working in the Field of Pharmaceutical Sciences Achieves EB1B Case Approval with the Help of Our Assistance
Client’s Testimonial:
“Thank you very much for your help with this. It was not possible without your firm.”
On March 15th, 2023, we received another EB-1B (Outstanding Professors and Researchers) approval for a Scientist in the Field of Pharmaceutical Sciences (Approval Notice).
General Field: Pharmaceutical Sciences
Position at the Time of Case Filing: Scientist
Country of Origin: India
State of Residence at the Time of Filing: Pennsylvania
Approval Notice Date: March 15th, 2023
Processing Time: 1 month, 19 days
Case Summary:
A Scientist contacted our law firm to help her establish her significant contributions to the U.S. by filing for an EB-1B (Outstanding Professors and Researchers) visa category. We presented her unique executive background and unprecedented experience necessary to her current and future work at the USCIS.
Upon reviewing her credentials, we found that our client has completed her:
- Ph.D. in Pharmaceutical Sciences in Medicinal Chemistry and has an unparalleled documented record of authorship in her field of endeavor.
- Her work has been published in some of the most prestigious, high-impact journals resulting in 13 peer-reviewed scientific articles.
- Moreover, she has already conducted at least 23 reviews for journals to date and her work has been cited by other scholars in numerous published articles as well. According to Google Scholar, her work has been cited a total of 224 times.
Furthermore, our client’s research addresses some of our nation’s most pressing issues in understanding the use of small molecules for improving the efficacy of cancer drugs. Her strong background in pharmacy and medicinal chemistry has allowed her research to be particularly original, with applications such as drug delivery, and cancer prevention and treatment. She is particularly well-known for her work on the structural modification of the aryl sulfonate ester of Cjoc42 for enhanced gankyrin binding and anti-cancer activity.
Her case was supported by four recommendation letters that she obtained from her fellow experts in the field, corroborating how her work has helped set the course for much subsequent research in this area. Therefore, one of the recommenders stated:
“Without question, [client] credentials and research expertise fully merit the continued opportunity to pursue further pharmaceutical research in the United States. The success, influence, and overall excellence of [client’s] work to date make it clear that she is a rising star in her field with the potential of advancing the field of pharmaceutical sciences for years to come.”
The totality of this evidence, thus shows that our client has been internationally recognized and fully qualified as an outstanding researcher in her field of expertise. Her impressive background, strong record of past achievements, recognition of expertise by journals seeking her services to review manuscripts, and unique knowledge relevant to her ongoing work all indicate that she not only qualifies as an outstanding researcher, but also that she is recognized internationally for her accomplishments within the field.
We would like to congratulate her on securing her EB1B case approval, which was adjudicated in only 2 months days instead of 9-12 months. We wish her to receive her green card as soon as possible.